atezolizumab

Details

Files
Generic Name:
atezolizumab
Project Status:
Complete
Therapeutic Area:
Small Cell Lung Cancer
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0277-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Tecentriq for the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 17, 2021
Call for patient/clinician input closedFebruary 18, 2022
Submission receivedJanuary 24, 2022
Submission acceptedFebruary 07, 2022
Review initiatedFebruary 08, 2022
Draft CADTH review report(s) provided to sponsor for commentApril 29, 2022
Deadline for sponsors commentsMay 10, 2022
CADTH review report(s) and responses to comments provided to sponsorJune 30, 2022
Expert committee meeting (initial)July 13, 2022
Draft recommendation issued to sponsorJuly 25, 2022
Draft recommendation posted for stakeholder feedbackAugust 04, 2022
End of feedback periodAugust 18, 2022
Final recommendation issued to sponsor and drug plansSeptember 01, 2022
Final recommendation postedSeptember 20, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)September 16, 2022
CADTH review report(s) postedDecember 8, 2022